Enzon PEG-ADA orphan product grant
The "Severe Combined Immunogencity Disease: Enzyme Therapy" grant provides a total of $169,908 for a three year period to fund the on-going development of the orphan PEG-adenosine deaminase (PEG-ADA) for treatment of children with Severe Combined Immunodeficiency Disease (SCID). FDA designated PEG-ADA an orphan product in 1985.
You may also be interested in...
The Q-Collar is meant to work by improving blood flow to the brain, and has been shown to reduce signs of trauma from head impacts when playing sports.
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.
Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.